Abbott Laboratories ABT recently announced that the FreeStyle Libre 2 system's reimbursement coverage has been expanded by the French health authority to cover individuals using basal insulin as part ...

Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) ...

Patients alarmed after glucose monitors used by diabetics are recalled after links to 7 deaths - Abbott recalled certain sensors used in its FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems, warni ...

A manufacturing problem in millions of Abbott glucose sensors has been tied to at least seven deaths and hundreds of injuries worldwide.

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...

- FreeStyle Libre 2 system continuously measures glucose data every minute with customizable, optional real-time alarms 1 to alert users when their glucose is high or low without scanning - Now for ...

"The best healthcare solution is the one that helps the most people, which is why we designed our FreeStyle Libre portfolio with access and affordability in mind from the very beginning," said ...

The Food and Drug Administration (FDA) has cleared the FreeStyle ® Libre 2 iOS App for use with the FreeStyle Libre 2 14-day glucose sensors in individuals 4 years of age and older with diabetes. The ...